NCT00916201

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Central Institute of Mental Health, Mannheim · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	URB597	10 mg / d for 5 days, orally
DRUG	intranasal Insulin	160 IU / d for 5 days, intranasal
DRUG	Cannabidiol CR	320 mg / d for 5 days, orally

Timeline

• Start date: 2025-01-31
• Primary completion: 2025-01-31
• Completion: 2025-01-31
• First posted: 2009-06-09
• Last updated: 2025-03-21

Locations

1 site across 1 country: Germany